ClinicalTrials.gg
CompletedNCT07143227Updated May 20, 2026

A Study of XW003 Injection in Chinese Adolescents With Obesity

A Phase 1 interventional study of XW003 injection and placebo with matching volume in Obese Adolescents and Obesity, sponsored by Hangzhou Sciwind Biosciences Co., Ltd.. Completed at 1 site in China. Open to participants aged 12 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by Hangzhou Sciwind Biosciences Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
12 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd. — 7 open to participants now, 8 under way, 4 of them phase 3. Obesity · Hangzhou Sciwind Biosciences Co., Ltd..

Enrollment
10th of 10
48 · median 152
Started
2025
with 2 others
Phase 1
2 of 10
1 open now
Registered
3rd of 10
by date

Among the 10 studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd., this one is the 10th largest by enrollment, is one of 3 that started in 2025, is one of 2 in phase 1, and was the 3rd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

7 of the 10 studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 12 Years to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd., or all of them as a file.
02

Study summary

The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XW003 injection in Chinese adolescents with obesity

Read the detailed description

In this study, eligible participants will be randomized into one of the three cohorts in a 3:1 ratio to receive either once-weekly subcutaneous XW003 injection or placebo, for up to 20 weeks.

03

Conditions studied

  • Obese Adolescents
  • Obesity

Browse trials for

Keywords

  • Weight management
  • obesity
  • XW003
  • ecnoglutide
  • glucagon-like peptide-1 (GLP-1)
  • adolescent
04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At the time of screening, meets the obesity criteria specified in WS/T586-2018 'screening for overweight and obesity among school-aged children and adolescents', and weight ≥55 kg;
  2. At the time of screening, the decrease of body mass index less than 5% after diet and exercise control alone for at least 12 weeks (as reported by participants or parents or legal guardians);

Exclusion criteria

Exclusion Criteria:

  1. Pre-adolescent participants (Tanner phase I);
  2. Obesity caused by secondary diseases or medications, including: elevated cortisol hormone (e.g. Cushing's syndrome), damage to the pituitary gland and hypothalamus, reduced dosage/discontinuation of weight-loss drugs or monogenic obesity, etc.;
  3. Have used any weight-loss drugs, hypoglycemic drugs, or drugs that may cause significant weight gain within 3 months prior to screening;
  4. Diagnosis with any type of diabetes;
  5. History of acute or chronic pancreatitis, history of gallbladder disease or pancreatic injury
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    XW003 Dose 1

    once weekly

    Drug: XW003 injection

  • Experimental
    XW003 Dose 2

    once weekly

    Drug: XW003 injection

  • Experimental
    XW003 Dose 3

    once weekly

    Drug: XW003 injection

  • Placebo comparator
    placebo

    once weekly

    Drug: placebo with matching volume

Interventions

  • Subcutaneous injection

  • Drugplacebo with matching volume

    Subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Number and severity of adverse events

    Time frame: week 20

Secondary outcomes

  1. Plasma concentrations of XW003

    Time frame: week 20

  2. Change of body weight from baseline

    Time frame: week 20

07

Study locations

1 site
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250012, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in Apr 2026, 7 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 7 months is below that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2025
First posted
Aug 27, 2025
StartActual
Aug 25, 2025
Primary completionActual
Apr 18, 2026
CompletionActual
Apr 18, 2026
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07143227
Lead sponsor
Hangzhou Sciwind Biosciences Co., Ltd.
Responsible party
Sponsor
First posted
Aug 27, 2025
Start date
Aug 25, 2025
Primary completion
Apr 18, 2026
Completion
Apr 18, 2026
Last update
May 20, 2026

Study contacts

Wei Zhao, Dr
principal investigator · Qilu Hospital of Shandong University
Xinguo Hou, Dr
principal investigator · Qilu Hospital of Shandong University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ecnoglutide

Start the discussion